316 related articles for article (PubMed ID: 34360568)
1. MicroRNAs, Multiple Sclerosis, and Depression.
Wang H
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360568
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs as biomarkers in progressive multiple sclerosis.
Vistbakka J; Elovaara I; Lehtimäki T; Hagman S
Mult Scler; 2017 Mar; 23(3):403-412. PubMed ID: 27246141
[TBL] [Abstract][Full Text] [Related]
3. Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis.
Zailaie SA; Siddiqui JJ; Al Saadi RM; Anbari DM; S Alomari A; Cupler EJ
Immunol Invest; 2022 May; 51(4):947-962. PubMed ID: 33660581
[TBL] [Abstract][Full Text] [Related]
4. Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis.
Morris G; Reiche EMV; Murru A; Carvalho AF; Maes M; Berk M; Puri BK
Mol Neurobiol; 2018 Aug; 55(8):6282-6306. PubMed ID: 29294244
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M
J Transl Med; 2015 May; 13():148. PubMed ID: 25947625
[TBL] [Abstract][Full Text] [Related]
6. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells.
Sanders KA; Benton MC; Lea RA; Maltby VE; Agland S; Griffin N; Scott RJ; Tajouri L; Lechner-Scott J
Clin Epigenetics; 2016; 8(1):87. PubMed ID: 27570566
[TBL] [Abstract][Full Text] [Related]
9. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
[TBL] [Abstract][Full Text] [Related]
10. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
[TBL] [Abstract][Full Text] [Related]
11. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.
Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ;
J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257
[TBL] [Abstract][Full Text] [Related]
12. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.
Lassmann H
Front Immunol; 2018; 9():3116. PubMed ID: 30687321
[TBL] [Abstract][Full Text] [Related]
13. Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability.
Mina Y; Azodi S; Dubuche T; Andrada F; Osuorah I; Ohayon J; Cortese I; Wu T; Johnson KR; Reich DS; Nair G; Jacobson S
Neuroimage Clin; 2021; 30():102680. PubMed ID: 34215150
[TBL] [Abstract][Full Text] [Related]
14. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
16. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
17. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
18. Highly active multiple sclerosis: An update.
Díaz C; Zarco LA; Rivera DM
Mult Scler Relat Disord; 2019 May; 30():215-224. PubMed ID: 30822617
[TBL] [Abstract][Full Text] [Related]
19. The fluctuations of expression profiles of critical genes in the miRNA maturation process and pro-and anti-inflammatory cytokines in the pathogenesis and progression of multiple sclerosis.
Khakdan F; Javanmard AS; Shahmoradipour P; Jahromi MJ
Mol Biol Rep; 2023 Nov; 50(11):9405-9416. PubMed ID: 37823932
[TBL] [Abstract][Full Text] [Related]
20. Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.
Kallaur AP; Lopes J; Oliveira SR; Simão AN; Reiche EM; de Almeida ER; Morimoto HK; de Pereira WL; Alfieri DF; Borelli SD; Kaimen-Maciel DR; Maes M
Mol Neurobiol; 2016 Oct; 53(8):5191-202. PubMed ID: 26399644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
